Fig. 1

PUS10 is decreased in RCC, and low expression of PUS10 predicts poor prognosis. A Kaplan‒Meier analysis showed the correlation between the expression of PUS10 and the overall survival of patients based on the TCGA cohort. B RT‒qPCR revealed the relative expression of PUS10 in 68 paired RCC tumors and normal tissues from our SRRSH cohort, normalized to GAPDH. C Expression of PUS10 in paired RCC tumor and normal tissue sequencing data in GSE53757. D Representative IHC images of PUS10 in 10 pairs of RCC tissues in the SRRSH cohort. E The IHC scores of each section were calculated. Dots, IHC score; lines, pairs of normal and tumor tissues. SRRSH, Sir Run Run Shaw Hospital. F Western blot assay showing the protein level of PUS10 in 10 pairs of RCC tissue from our cohort. G Pancancer analysis of the PUS10 level in multiple cancers based on the Human Protein Atlas database. H Relative expression of PUS10 in RCC tissues with or without metastasis. I Relative expression of PUS10 in RCC tissues with different TNM stages. J The frequency of relapse in RCC patients with low and high expression of PUS10, the low and high PUS10 expression groups were cut off by the median expression. K Kaplan‒Meier analysis showed the difference of disease free survival between low and high PUS10 expression groups. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant. Data are representative of three independent experiments